Litcius/Paper detail

EGFR Exon 20 Insertion (A763_Y764insFQEA) Mutant NSCLC Is Not Identified by Roche Cobas Version 2 Tissue Testing but Has Durable Intracranial and Extracranial Response to Osimertinib

Niamh Coleman, David Woolf, Liam Welsh, Fiona McDonald, Suzanne MacMahon, Nadia Yousaf, Sanjay Popat

2020Journal of Thoracic Oncology22 citationsDOI

Topics & Concepts

MedicineOsimertinibLung cancerEpidermal growth factor receptorExonAdenocarcinomaGefitinibROS1ErlotinibAfatinibImmunohistochemistryOncologyCancer researchCancerInternal medicinePathologyGeneBiologyGeneticsLung Cancer Treatments and MutationsColorectal Cancer Treatments and StudiesLung Cancer Research Studies
EGFR Exon 20 Insertion (A763_Y764insFQEA) Mutant NSCLC Is Not Identified by Roche Cobas Version 2 Tissue Testing but Has Durable Intracranial and Extracranial Response to Osimertinib | Litcius